HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐Effectiveness
Clinical Infectious Diseases2009Vol. 48(6), pp. 806–815
Citations Over TimeTop 1% of 2009 papers
A. David Paltiel, Kenneth A. Freedberg, Callie A. Scott, Bruce R. Schackman, Elena Losina, Bingxia Wang, George R. Seage, Caroline E. Sloan, Paul E. Sax, Rochelle P. Walensky
Abstract
PrEP could substantially reduce the incidence of HIV transmission in populations at high risk of HIV infection in the United States. Although it is unlikely to confer sufficient benefits to justify the current costs of tenofovir-emtricitabine, price reductions and/or increases in efficacy could make PrEP a cost-effective option in younger populations or populations at higher risk of infection. Given recent disappointments in HIV infection prevention and vaccine development, additional study of PrEP-based HIV prevention is warranted.
Related Papers
- → Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention(2012)302 cited
- → CDC promotes pre-exposure prophylaxis for HIV prevention(2014)1 cited
- → HIV pre-exposure prophylaxis(2014)1 cited
- → Tenofovir-Based HIV Pre-Exposure Prophylaxis(2013)1 cited
- → [Research advances in HIV pre-exposure prophylaxis drug].(2022)1 cited